cinacalcet has been researched along with Osteoporosis in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ogrin, C | 1 |
| Bouquegneau, A; Delanaye, P; Eastell, R; Khwaja, A; Salam, S | 1 |
| Dillon, ML; Frazee, LA | 1 |
| Lopez, J; Norman, J; Politz, D | 1 |
| Abreu, C; Castro, JC; Díez, JJ; Iglesias, P | 1 |
| Imanishi, Y | 1 |
| Nemeth, EF | 2 |
| Chattopadhyay, N; Mithal, A; Trivedi, R | 1 |
5 review(s) available for cinacalcet and Osteoporosis
| Article | Year |
|---|---|
Bone Disease after Kidney Transplantation.
Topics: Absorptiometry, Photon; Bone Density Conservation Agents; Bone Diseases; Calcimimetic Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Fractures, Bone; Humans; Immunosuppression Therapy; Kidney Transplantation; Minerals; Osteoporosis; Parathyroid Hormone; Vitamin D; Vitamins | 2016 |
Cinacalcet for the treatment of primary hyperparathyroidism.
Topics: Bone Density; Bone Density Conservation Agents; Calcimimetic Agents; Calcitonin; Cinacalcet; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Female; Humans; Hyperparathyroidism, Primary; Naphthalenes; Osteoporosis; Raloxifene Hydrochloride | 2011 |
[Kidney and bone update : the 5-year history and future of CKD-MBD. Bone fragility in the aged hemodialysis patients].
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Chronic Disease; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Diphosphonates; Fractures, Spontaneous; Homeostasis; Humans; Kidney Diseases; Minerals; Naphthalenes; Osteoporosis; Phosphorus; Renal Dialysis; Risk | 2012 |
Calcimimetic and calcilytic drugs: just for parathyroid cells?
Topics: Aniline Compounds; Animals; Calcium; Calcium Channels; Cinacalcet; Fendiline; Humans; Hyperparathyroidism; Naphthalenes; Osteoporosis; Parathyroid Glands; Phenethylamines; Propylamines; Receptors, Calcium-Sensing; Stereoisomerism | 2004 |
Recent updates on the calcium-sensing receptor as a drug target.
Topics: Allosteric Regulation; Animals; Calcium; Cinacalcet; Clinical Trials as Topic; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Osteoporosis; Parathyroid Glands; Parathyroid Hormone; Receptors, Calcium-Sensing; Receptors, GABA-B | 2008 |
4 other study(ies) available for cinacalcet and Osteoporosis
| Article | Year |
|---|---|
Evaluation of parathyroid levels and bone densitometry after cinacalcet treatment in severe primary hyperparathyroidism.
Topics: Alkaline Phosphatase; Bone Density; Calcium; Cinacalcet; Diphosphonates; Female; Follow-Up Studies; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Ibandronic Acid; Naphthalenes; Osteoporosis; Parathyroid Hormone; Phosphates; Vitamin D | 2013 |
Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Calcium; Cinacalcet; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Primary; Male; Middle Aged; Naphthalenes; Nausea; Osteoporosis; Treatment Failure; Vomiting; Young Adult | 2012 |
[Long-term combined treatment with cinacalcet and bisphosphonates in persistent primary hyperparathyroidism after surgery].
Topics: Alendronate; Bone Density Conservation Agents; Cinacalcet; Drug Therapy, Combination; Female; Humans; Hypercalcemia; Hypercalciuria; Hyperparathyroidism, Primary; Hyperphosphatemia; Middle Aged; Naphthalenes; Osteoporosis; Postoperative Complications | 2012 |
Summary--calcium receptors: potential targets for novel treatments for skeletal disease.
Topics: Bone and Bones; Calcium; Cinacalcet; Humans; Hyperparathyroidism; Naphthalenes; Osteoporosis; Parathyroid Hormone; Receptors, Calcium-Sensing | 2004 |